Trial Initiated to Study Adcetris with R-CHOP in DLBCL Patients

Seattle Genetics has announced the launch of a phase II clinical trial evaluating Adcetris (brentuximab vedotin) in combination with R-CHOP (therefore called A+R-CHOP) for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL).

About the trial

The trial will evaluate the complete remission rate and safety of the A+RCHOP regimen. Currently, Adcetris is not market approved to treat DLBCL.

R-CHOP remains the standard of care in the frontline treatment of DLBCL, a non-Hodgkin's lymphoma that is the most commonly diagnosed lymphoma subtype.

Clay B. Siegall, Ph.D., president and chief executive officer at Seattle Genetics said:

The encouraging data we have observed in our phase II trial of Adcetris in relapsed non-Hodgkin's lymphoma, including DLBCL patients, support evaluation in earlier lines of therapy for patients with this aggressive lymphoma type. This trial will provide us with data on the tolerability of the combination, as well as the antitumor activity achieved by adding Adcetris to the current standard frontline regimen. In addition, based on interim findings from our trial in the relapsed setting in which objective responses were observed among patients with low or undetectable levels of CD30 by conventional screening methods, we will enroll high-risk DLBCL patients to this frontline trial without prescreening for CD30 expression.

Phase II

This phase II trial is designed as an open-label clinical trial that will recruit about 50 frontline high-risk DLBCL patients. They will receive Adcetris along with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (A+RCHOP).

Patients will be randomized to receive standard dose RCHOP with either 1.2 milligrams per kilogram (mg/kg) or 1.8 mg/kg of Adcetris. The trial will enroll patients regardless of CD30 expression level by immunohistochemistry to further explore previously reported data that shows some objective responses in patients with varying levels of CD30.

The primary endpoints are to assess the complete remission rate and safety profile of the combination. Secondary endpoints include objective response rate, progression-free survival and overall survival.

Source: WSJ

More Articles

More Articles

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

Canine lymphoma, just like lymphoma in humans, can be separated into stages,...